Self-assembly of multi-specific antibodies for efficient cancer immunotherapy
This technology is a therapeutic platform that enables the selective removal of diseased or cancerous cells with few side effects.
Unmet Need: Personalized approach for highly selective and antibody-based elimination of diseased cells
Current treatments for cancer and immunological disease often lead to damage of healthy subpopulations of cells that share cell-surface markers with the diseased cells. Conventional treatment methods use bispecific antibodies to bind two or more antigens. However, these therapies have low specificity for their target and result in side effects.
The Technology: Therapeutic platform using customizable antibody pairs for cancer immunotherapy
This platform is comprised of multi-specific antibody pairs that self-assemble at the cell surface for the selective elimination of diseased cells. Antibody pairings on the same cell are crosslinked. This then triggers various events, such as internalization or activation of death receptor signaling pathways, and toxin delivery by attaching a load to the first antibody. This highly specified method of targeted antibody crosslinking avoids the side effects of conventional bispecific antibody-based immunotherapy.
Applications:
- Therapeutic for cancer or immunological disorders
- Immunotherapy for HIV
- Research model for studying targeted self-assembly of antibodies.
- Research tool for studying T cell and NK cell function
Advantages:
- Modular platform
- Easily customized antibody pairing
- Minimizes side-effects of standard therapies
- Suitable for in vivo use in clinical settings
- Allows quick assessment of personalized response
Lead Inventor:
Patent Information:
Related Publications:
Tech Ventures Reference:
IR CU21275
Licensing Contact: Jerry Kokoshka